Systemic juvenile idiopathic arthritis (sJIA)

Background

  • Systemic juvenile idiopathic arthritis (sJIA) is also known as Still's disease (the adult form is adult-onset Still's disease)
  • An autoinflammatory disease (driven by innate immune system and IL-1/IL-6), distinct from other forms of JIA which are autoimmune[1]
  • Children <16 years; accounts for 10-20% of all JIA but contributes approximately two-thirds of JIA-related mortality[2]
  • Peak onset age 1-5 years; equal sex distribution (unlike other JIA subtypes)
  • Most important differential diagnosis in a child presenting with prolonged fever of unknown origin
  • sJIA is a diagnosis of exclusion — must rule out infection and malignancy first

ILAR Classification Criteria

Arthritis in ≥1 joint with, or preceded by, fever of ≥2 weeks duration that is documented to be quotidian (daily) for ≥3 days, PLUS ≥1 of the following:[3]

  1. Evanescent (nonfixed) erythematous rash
  2. Generalized lymphadenopathy
  3. Hepatomegaly and/or splenomegaly
  4. Serositis (pericarditis, pleuritis, or peritonitis)

Exclusions: Psoriasis in patient or first-degree relative, arthritis in HLA-B27+ male with onset after age 6, ankylosing spondylitis/ERA/sacroiliitis with IBD/reactive arthritis/acute anterior uveitis in first-degree relative, positive IgM RF on ≥2 occasions ≥3 months apart

Clinical Features

Fever

  • Quotidian (daily spiking) pattern: temperature spikes to ≥39°C (102.2°F), typically 1-2 times daily (often late afternoon/evening), with return to normal or below normal baseline between spikes[4]
  • Child may appear profoundly ill during fever spikes and remarkably well between them — this pattern is highly suggestive
  • The classic quotidian pattern is observed in only ~37% of patients; atypical fever patterns are common[4]
  • Duration ≥2 weeks by definition
  • ED Pearl: Evolution from intermittent spiking fever to continuous high fever should raise concern for macrophage activation syndrome (MAS)

Rash

  • Evanescent (comes and goes), salmon-pink, macular or maculopapular
  • Appears during fever spikes, resolves with defervescence — may be absent when the child is afebrile in the ED
  • Trunk, proximal extremities, axillae, neck; spares face
  • Non-pruritic, non-fixed, leaves no residual scarring or pigmentation
  • Koebner phenomenon: rash may appear at sites of skin scratching or pressure[4]
  • May be difficult to appreciate in dark-skinned children — examine during active fever

Arthritis

  • May be oligoarticular or polyarticular; wrists, knees, and ankles most commonly affected
  • Arthritis may be delayed — systemic features can precede joint involvement by weeks to months
  • Cervical spine and temporomandibular joint involvement more common in sJIA than other JIA subtypes

Other Features

Macrophage Activation Syndrome (MAS)

The most life-threatening complication of sJIA. Occurs in ~10% overtly, up to 30% subclinically.[5]

  • A form of secondary hemophagocytic lymphohistiocytosis (HLH) — massive cytokine storm
  • Triggers: viral infections, medication changes, disease flares
  • Clinical red flags for MAS:
    • Change in fever pattern from intermittent to continuous
    • Worsening despite treatment, or rapid deterioration
    • New or worsening hepatomegaly
    • Hemorrhagic manifestations (bruising, mucosal bleeding)
    • Encephalopathy, altered mental status
    • Paradoxical drop in ESR (due to fibrinogen consumption) while ferritin is markedly elevated
  • Lab hallmarks of MAS:
    • Hyperferritinemia (often >10,000 ng/mL; markedly disproportionate to other acute phase reactants)
    • ↓ Fibrinogen (consumption)
    • ↓ Platelets (falling trend, even if still "normal")
    • ↓ WBC (falling trend)
    • ↑ AST/ALT (liver involvement)
    • ↑ Triglycerides
    • ↑ LDH
    • ↑ D-dimer / ↓ ESR (paradoxical — ESR drops as fibrinogen is consumed)
  • ED Pearl: A falling platelet count, falling ESR, or rising ferritin in a child with sJIA should be considered MAS until proven otherwise and warrants emergent rheumatology and/or hematology consultation

Differential Diagnosis

sJIA is a diagnosis of exclusion. The following must be considered before attributing findings to sJIA:

Critical to Exclude

  • Leukemia/lymphoma — most important mimicker; can present with fever, arthralgia, hepatosplenomegaly, lymphadenopathy, and cytopenias
  • Sepsis/bacteremia — especially endocarditis
  • Kawasaki disease — prolonged fever, rash, lymphadenopathy (but typically <5 days fever at presentation, and specific mucocutaneous criteria)
  • Neuroblastoma and other solid tumors

Other Differential

Pediatric limp

Hip Related

Other Causes of Limping

Polyarthritis

Algorithm for Polyarticular arthralgia

Evaluation

Workup

  • CBC with differential:
    • Leukocytosis (often marked; WBC >15,000-50,000+; sometimes leukemoid reaction)
    • Anemia (hypochromic, microcytic — anemia of chronic disease)
    • Thrombocytosis (reactive) — a falling platelet count suggests MAS
  • ESR, CRP: markedly elevated; paradoxical drop in ESR with rising CRP suggests MAS
  • Ferritin: often very elevated in active sJIA (typically >500 ng/mL); ferritin >10,000 ng/mL strongly suggests MAS[5]
  • Fibrinogen: normal or elevated in active sJIA; falling fibrinogen suggests MAS
  • LFTs: may be elevated; transaminitis suggests MAS or hepatic involvement
  • LDH, triglycerides, D-dimer: to screen for MAS
  • Blood culture: mandatory to exclude bacteremia/sepsis
  • Peripheral blood smear: to evaluate for blasts (leukemia) and hemophagocytes
  • Coagulation studies (PT/PTT): may be prolonged in MAS/DIC
  • Consider: procalcitonin (may help differentiate infection from sJIA flare, though not definitive), uric acid, urinalysis

Imaging

Diagnosis

  • Clinical diagnosis based on ILAR criteria (see Background) after exclusion of infection and malignancy
  • Arthrocentesis may be needed to exclude septic arthritis — especially if monoarticular presentation
  • Bone marrow biopsy may be required to exclude leukemia if clinical concern exists, particularly before starting corticosteroids (which can mask leukemia)
  • ANA and RF are typically negative in sJIA (if positive, consider other diagnoses)
  • No single diagnostic test is confirmatory — the diagnosis rests on the combination of clinical features and exclusion of mimickers

Management

Management in the ED is focused on stabilization, diagnostic workup, and rheumatology consultation. Definitive treatment is guided by pediatric rheumatology.

Acute ED Management

  • Hemodynamic stabilization if MAS or sepsis is suspected
  • Empiric antibiotics until sepsis/bacterial infection can be excluded (these patients often appear septic)
  • NSAIDs for fever, pain, and mild-moderate disease:
    • Naproxen 10-15 mg/kg/day divided BID (most commonly used NSAID in sJIA)
    • Ibuprofen 30-40 mg/kg/day divided TID-QID
  • Corticosteroids may be initiated if:
    • Diagnosis is certain (infection and malignancy excluded)
    • Severe systemic illness, pericarditis, or MAS
    • Typically methylprednisolone IV pulse (30 mg/kg, max 1g) for severe disease or MAS, or prednisone 1-2 mg/kg/day PO for moderate disease
    • Do not start steroids before obtaining a peripheral smear and ideally a bone marrow biopsy if leukemia has not been excluded[1]
  • If MAS suspected: emergent rheumatology and/or hematology consultation; high-dose IV corticosteroids are first-line; may require cyclosporine or anakinra

Definitive Therapy (Rheumatology-Directed)

  • IL-1 inhibitors (anakinra, canakinumab) and IL-6 inhibitors (tocilizumab) are first-line biologic agents for moderate-severe sJIA[6]
  • Goal is early aggressive therapy to achieve remission and minimize corticosteroid exposure
  • Anakinra (IL-1 receptor antagonist) may be started in the ED or inpatient setting by rheumatology for severe/refractory disease or MAS

Consults

  • Pediatric rheumatology: All patients with suspected sJIA
  • Pediatric hematology/oncology: If leukemia/malignancy is on the differential, or if MAS is suspected
  • Cardiology: If significant pericardial effusion or concern for cardiac tamponade

Disposition

  • Admit — nearly all patients with suspected new-onset sJIA require admission for:
    • Diagnostic workup to exclude infection and malignancy
    • Monitoring for MAS (which can develop at any point)
    • Initiation of treatment
    • Rheumatology consultation
  • ICU admission if:
    • MAS with hemodynamic instability, coagulopathy, or organ dysfunction
    • Significant pericardial effusion with hemodynamic compromise
    • Respiratory distress from pleural effusion or pulmonary disease

See Also

External Links

References

  1. ↑ 1.0 1.1 Juvenile Idiopathic Arthritis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
  2. ↑ Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133-8.
  3. ↑ Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-2.
  4. ↑ 4.0 4.1 4.2 Spoorthy Raj DR, Suma Balan. Systemic Juvenile Idiopathic Arthritis: The Challenges and Opportunities. Indian J Rheumatol. 2024.
  5. ↑ 5.0 5.1 Ravelli A, Minoia F, Davì S, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016;68(3):566-76.
  6. ↑ Ringold S, Angeles-Han ST, Engel ME, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res. 2022;74(4):521-533.
Retrieved from "https://www.wikem.org/w/index.php?title=Systemic_juvenile_idiopathic_arthritis_(sJIA)&oldid=389318"